CalciMedica, Inc. Receives Nasdaq Non-Compliance Notices for Market Value and Minimum Bid Price Requirements

CalciMedica, Inc. (NASDAQ: CALC) has announced that it received two separate notifications from The Nasdaq Stock Market LLC, indicating the company is not in compliance with key continued listing requirements. These developments are highly significant for investors, as failure to regain compliance could result in the company’s shares being delisted from the Nasdaq Capital Market.

Key Points from the Report

• Non-Compliance with Market Value of Listed Securities (MVLS) Requirement:
  • On March 13, 2026, CalciMedica received notice from Nasdaq stating the company’s market value of listed securities (MVLS) had been below the required minimum of \$35 million for the past 30 consecutive business days.
  • The company also does not meet alternative standards related to stockholders’ equity and net income under Nasdaq Listing Rules 5550(b)(1) and 5550(b)(3).
  • CalciMedica has 180 calendar days (until September 9, 2026) to regain compliance. The company can do this by meeting one of the following:
    • Maintaining stockholders’ equity of at least \$2.5 million.
    • Having a market value of listed securities of at least \$35 million.
    • Reporting net income from continuing operations of \$500,000 in the most recent fiscal year or in two of the three most recent fiscal years.
  • To regain compliance with the MVLS, the company’s market value of listed securities must close at or above \$35 million for at least 10 consecutive business days within the 180-day period.
  • If the company fails to regain compliance, Nasdaq may move to delist CalciMedica’s securities.
• Non-Compliance with Minimum Bid Price Requirement:
  • On March 16, 2026, CalciMedica received a separate notice from Nasdaq indicating that the company’s common stock had traded below the required minimum bid price of \$1.00 per share for 30 consecutive business days.
  • Under Nasdaq Listing Rule 5810(c)(3)(A), CalciMedica has 180 calendar days (until September 14, 2026) to regain compliance by having its closing bid price at or above \$1.00 per share for at least 10 consecutive business days within the 180-day period.
  • If compliance is not achieved by that date, CalciMedica may still be eligible for a second 180-day compliance period, provided it meets other initial listing standards (excluding the minimum bid price) and notifies Nasdaq of its intent to cure the deficiency, potentially including actions like a reverse stock split.
  • If CalciMedica does not indicate its intent to cure, or if Nasdaq determines it is not possible to cure, no second compliance period will be granted and the company could face delisting.
• Immediate Impact:
  • These notifications do not have an immediate effect on the listing or trading of CalciMedica’s common stock, which continues to trade on the Nasdaq Capital Market under the symbol CALC.
  • However, the risk of delisting is material and may negatively impact investor confidence and share price in the near term.

What Investors and Shareholders Need to Know

• Both Nasdaq notices are material and represent significant risks to the company’s continued listing on the Nasdaq Capital Market.
• Loss of Nasdaq listing could severely affect liquidity and the market value of CalciMedica’s shares.
• The company is considering all available options to regain compliance, including conducting a reverse stock split if necessary.
• There can be no assurance that CalciMedica will be able to regain compliance with the Nasdaq listing rules within the specified periods or at all.
• Failure to resolve these deficiencies could lead to delisting, which would have a substantial negative impact on shareholder value.

Conclusion

These developments are highly significant for shareholders and potential investors. The company’s ability to maintain its Nasdaq listing is at risk, and any actions taken (such as a reverse stock split, equity raise, or operational improvement) will be closely watched by the market. The outcome of this process will likely have a material impact on CalciMedica’s stock price in the coming months.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult with a qualified financial advisor before making any investment decisions. The author and publisher accept no responsibility for any loss that may arise from reliance on information contained in this article.

View CalciMedica, Inc. Historical chart here